keyword
MENU ▼
Read by QxMD icon Read
search

Protocol chemotherapy for lung cancer

keyword
https://www.readbyqxmd.com/read/30621712/living-donor-liver-transplantation-with-two-stage-hepatectomy-for-patients-with-isolated-irresectable-colorectal-liver-the-liver-t-w-o-heal-study
#1
Falk Rauchfuß, Silvio Nadalin, Alfred Königsrainer, Utz Settmacher
BACKGROUND: Colorectal cancer is the third most common malignancy worldwide. The occurrence of liver metastases worsens the prognosis of the patient significantly if the tumor burden is not resectable. Liver transplantation might be an option for otherwise irresectable colorectal liver metastases. In this study, we evaluate the role of two-stage hepatectomy in combination with a left-lateral living donor liver transplantation. METHODS: Patients with irresectable liver metastases having a stable disease or tumor regression after at least 8 weeks of systemic chemotherapy without an extrahepatic tumor burden (except resectable lung metastases) are suitable for study inclusion...
January 8, 2019: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/30607130/does-the-presence-of-emphysema-increase-the-risk-of-radiation-pneumonitis-in-lung-cancer-patients
#2
G Kasymjanova, R T Jagoe, C Pepe, L Sakr, V Cohen, D Small, T M Muanza, J S Agulnik
Introduction: Radiotherapy (rt) plays an important role in the treatment of lung cancer. One of the most common comorbidities in patients with lung cancer is pulmonary emphysema. The literature offers conflicting data about whether emphysema increases the occurrence and severity of radiation pneumonitis (rp). As a result, whether high doses of rt (with curative intent) should be avoided in patients with emphysema is still unclear. Objective: We measured the documented incidence of rp in patients with and without emphysema who received curative radiation treatment...
December 2018: Current Oncology
https://www.readbyqxmd.com/read/30558074/characterisation-of-gut-lung-and-upper-airways-microbiota-in-patients-with-non-small-cell-lung-carcinoma-study-protocol-for-case-control-observational-trial
#3
Rea Bingula, Marc Filaire, Nina Radosevic-Robin, Jean-Yves Berthon, Annick Bernalier-Donadille, Marie-Paule Vasson, Emilie Thivat, Fabrice Kwiatkowski, Edith Filaire
BACKGROUND: Several studies have confirmed the important role of the gut microbiota in the regulation of immune functions and its correlation with different diseases, including cancer. While brain-gut and liver-gut axes have already been demonstrated, the existence of a lung-gut axis has been suggested more recently, with the idea that changes in the gut microbiota could affect the lung microbiota, and vice versa. Likewise, the close connection between gut microbiota and cancer of proximal sites (intestines, kidneys, liver, etc...
December 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/30523756/randomized-phase-ii-trial-of-cisplatin-and-etoposide-in-combination-with-veliparib-or-placebo-for-extensive-stage-small-cell-lung-cancer-ecog-acrin-2511-study
#4
Taofeek K Owonikoko, Suzanne E Dahlberg, Gabriel L Sica, Lynne I Wagner, James L Wade, Gordan Srkalovic, Bradley W Lash, Joseph W Leach, Ticiana B Leal, Charu Aggarwal, Suresh S Ramalingam
PURPOSE: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC). MATERIALS AND METHODS: Patients with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assigned to receive four 3-week cycles of CE (75 mg/m2 intravenously on day 1 and 100 mg/m2 on days 1 through 3) along with veliparib (100 mg orally twice per day on days 1 through 7) or placebo (CE+P)...
December 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30515212/small-or-non-small-cell-lung-cancer-based-therapy-for-treatment-of-large-cell-neuroendocrine-cancer-of-the-lung-university-of-cincinnati-experience
#5
Ihab Eldessouki, Ola Gaber, Tariq Namad, Jiang Wang, John C Morris, Nagla Abdel Karim
Large cell neuroendocrine cancer (LCNEC) of the lung exhibits morphological and immunohistochemical characteristics of both neuroendocrine and large cell carcinomas. No defined optimal therapy has been described for this subset of patients and the question of whether these patients should be treated with non-small cell lung cancer (NSCLC) treatment protocols, according to the National Comprehensive Cancer Network (NCCN) guidelines, or with small cell lung cancer (SCLC) due to histological and clinical similarities is still uncertain...
2018: Journal of Oncology
https://www.readbyqxmd.com/read/30514667/phase-2-study-of-afatinib-alone-or-combined-with-bevacizumab-in-chemonaive-patients-with-advanced-non-small-cell-lung-cancer-harboring-egfr-mutations-afabev-cs-study-protocol
#6
Takashi Ninomiya, Nobuhisa Ishikawa, Koji Inoue, Toshio Kubo, Masayuki Yasugi, Takuo Shibayama, Tadashi Maeda, Kazunori Fujitaka, Masahiro Kodani, Toshihide Yokoyama, Shoichi Kuyama, Nobuaki Ochi, Yutaka Ueda, Seigo Miyoshi, Toshiyuki Kozuki, Yoshihiro Amano, Tetsuya Kubota, Keisuke Sugimoto, Akihiro Bessho, Tomoya Ishii, Kazuhiko Watanabe, Isao Oze, Katsuyuki Hotta, Katsuyuki Kiura
Afatinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has demonstrated a significant survival benefit over platinum-based chemotherapy in a first-line setting in advanced non-small-cell lung cancer (NSCLC) harboring EGFR exon 19 deletion. In addition, we and other groups have shown there to be favorable progression-free survival (PFS) outcomes, with acceptable toxicity profiles, with bevacizumab and first-generation EGFR-TKI combination therapy. On the basis of the above, we hypothesized that a combination of bevacizumab and afatinib could potentially improve efficacy...
November 1, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/30497431/a-pilot-study-of-stereotactic-body-radiation-therapy-sbrt-after-surgery-for-stage-iii-non-small-cell-lung-cancer
#7
Anurag K Singh, Mark Hennon, Sung Jun Ma, Todd L Demmy, Anthony Picone, Elizabeth U Dexter, Chumy Nwogu, Kristopher Attwood, Wei Tan, Gregory M Hermann, Simon Fung-Kee-Fung, Harish K Malhotra, Sai Yendamuri, Jorge A Gomez-Suescun
BACKGROUND: Standard therapy for stage III non-small cell lung cancer with chemotherapy and conventional radiation has suboptimal outcomes. We hypothesized that a combination of surgery followed by stereotactic body radiation therapy (SBRT) would be a safe alternative. METHODS: Patients with stage IIIA (multistation N2) or IIIB non-small cell lung cancer were enrolled from March 2013 to December 2015. The protocol included transcervical extended mediastinal lymphadenectomy (TEMLA) followed by surgical resection, 10 Gy SBRT directed to the involved mediastinum/hilar stations and/or positive surgical margins, and adjuvant systemic therapy...
November 29, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30460541/immunomodulatory-effect-of-lentinan-on-aberrant-t-subsets-and-cytokines-profile-in-non-small-cell-lung-cancer-patients
#8
Xi-En Wang, You-Hui Wang, Qiang Zhou, Min Peng, Jing Zhang, Mi Chen, Li-Juan Ma, Guo-Ming Xie
As a purified active component from traditional Chinese medicine, lentinan administration can be applied as beneficial chemo-immunotherapy for anti-tumor. In this study, the immunomodulatory effects of lentinan on aberrant T subsets and cytokines profile were evaluated for non-small cell lung cancer (NSCLC). Of all NSCLC patients treated with NP chemotherapeutic protocol (combination of vinorelbin and cisplatin), 73 cases were recruited in this retrospective cohort trial study, of which 38 cases received additional lentinan...
November 20, 2018: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/30443292/integration-of-stereotactic-radiotherapy-in-the-treatment-of-metastatic-colorectal-cancer-patients-a-real-practice-study-with-long-term-outcome-and-prognostic-factors
#9
Alessandro Ottaiano, Valerio Scotti, Chiara De Divitiis, Monica Capozzi, Carmen Romano, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Anna Nappi, Valeria Vicario, Alfonso De Stefano, Salvatore Tafuto, Massimiliano Berretta, Guglielmo Nasti, Antonio Avallone
Background: There are very few clinical or prognostic studies on the role of SRT (Stereotactic Radiation Therapy) in the continuum of care of metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients affected by oligo-mCRC were treated with SRT before or after front-line standard treatments. SRT was delivered according to a risk-adapted protocol. Total body CT (Computed Tomography) scan was done before therapy and every three months thereafter...
October 16, 2018: Oncotarget
https://www.readbyqxmd.com/read/30429415/rationale-and-design-of-a-randomized-phase-2-trial-of-gefitinib-plus-bevacizumab-vs-gefitinib-alone-in-patients-with-epidermal-growth-factor-receptor-mutant-non-squamous-non-small-cell-lung-cancer-study-protocol
#10
Chiyoe Kitagawa, Akiko Kada, Akiko M Saito, Yukito Ichinose, Hideo Saka
Combination chemotherapy with platinum preparations is the standard first-line treatment for stage IIIB/IV non-small-cell lung cancer. However, the median survival in patients receiving this therapy is 8 to 10 months, and it is essential to improve the results of chemotherapy in non-small-cell lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors hinder EGFR signal transmission by binding to the adenosine triphosphate binding site of intracellular tyrosine kinase and inhibiting the autophospholylation of EGFR...
November 15, 2018: Kurume Medical Journal
https://www.readbyqxmd.com/read/30429034/predicting-survival-following-surgical-resection-of-lung-cancer-using-clinical-and-pathological-variables-the-development-and-validation-of-the-lnc-path-score
#11
Haval Balata, Philip Foden, Tim Edwards, Anshuman Chaturvedi, Mohamed Elshafi, Alexander Tempowski, Benjamin Teng, Paul Whittemore, Kevin G Blyth, Andrew Kidd, Deborah Ellames, Louise Ann Flint, Jonathan Robson, Elaine Teh, Robin Jones, Timothy Batchelor, Philip Crosbie, Richard Booton, Matthew Evison
INTRODUCTION: The aim of this study was to develop and validate a simple prognostic scoring system using readily available clinical and pathological variables that could stratify patients according to the risk of death following lung cancer resection. We hypothesized that by using additional pathological variables not accounted for by pathological stage alone coupled with markers of overall fitness a new prognostic tool could be developed. METHODS: Multivariable logistic regression analysis of pathological and other clinical variables from patients undergoing surgical resection of non-small cell lung cancer (NSCLC) were used to determine factors independently associated with 2-year overall survival and so derive the scoring system...
November 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30416904/immunotherapy-in-advanced-non-small-cell-lung-cancer-patients-ushering-chemotherapy-through-the-checkpoint-inhibitors
#12
REVIEW
Bushra Kanwal, Sharmi Biswas, Robert S Seminara, Charan Jeet
New ways of exploiting the immune system for cancer treatment have been tested for decades with moderate outcomes. Based on previous immunotherapy knowledge, agents targeting immune checkpoints seem to be remarkably effective in a wide range of tumors. Immune checkpoint inhibitors in metastatic non-small cell lung cancer (NSCLC) provide longlasting responses in specific patients. Nevertheless, with overall response rates ≤ 20%, combinational protocols for various patient subgroups are needed. A good partner treatment to immunotherapy could be chemotherapy, as it successfully modulates the immune response either by controlling or enhancing the antitumor immune activity...
September 4, 2018: Curēus
https://www.readbyqxmd.com/read/30391573/compliance-and-outcome-of-elderly-patients-treated-in-the-concurrent-once-daily-versus-twice-daily-radiotherapy-convert-trial
#13
Marianna Christodoulou, Fiona Blackhall, Hitesh Mistry, Ahmet Leylek, Joost Knegjens, Vincent Remouchamps, Isabelle Martel-Lafay, Núria Farré, Matjaž Zwitter, Delphine Lerouge, Nicolas Pourel, Henri Janicot, Arnaud Scherpereel, Caroline Tissing-Tan, Karin Peignaux, Xavier Geets, Krzysztof Konopa, Corinne Faivre-Finn
INTRODUCTION: There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited-stage, patients with SCLC. METHODS: We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once-daily Versus twice-daily RadioTherapy (CONVERT) trial. Patients were randomized to receive 45 Gy/30 twice-daily fractions/19 days or 66 Gy/33 once-daily fractions/45 days concurrently with platinum-based chemotherapy...
October 31, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/30340555/possible-involvement-of-interleukin-18-in-the-pathology-of-hepatobiliary-adverse-effects-related-to-treatment-with-ceritinib
#14
Taizou Hirano, Akira Koarai, Tomohiro Ichikawa, Teruyuki Sato, Takashi Ohe, Masakazu Ichinose
BACKGROUND: Ceritinib demonstrated a statistically significant effect on the progression-free survival versus chemotherapy in patients with advanced anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) as the first therapy or after previous treatment with crizotinib and one or two prior chemotherapy regimens in global phase 3 studies. However, some serious adverse effects related to ceritinib therapy were reported across these clinical studies. Among them, a grade 3 and 4 increase in hepatobiliary enzymes was one of the common adverse events related to treatment with ceritinib...
October 19, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30261853/engaging-the-older-cancer-patient-patient-activation-through-counseling-exercise-and-mobilization-pancreatic-biliary-tract-and-lung-cancer-pace-mobil-pbl-study-protocol-of-a-randomized-controlled-trial
#15
Marta Kramer Mikkelsen, Cecilia Margareta Lund, Anders Vinther, Anders Tolver, Anne-Mette Ragle, Julia Sidenius Johansen, Inna Chen, Lotte Engell-Noerregaard, Finn Ole Larsen, Bo Zerahn, Dorte Lisbet Nielsen, Mary Jarden
BACKGROUND: Several intervention studies have demonstrated that exercise training has beneficial effects among cancer patients. However, older cancer patients are underrepresented in clinical trials, and only few exercise-based studies have focused specifically on older patients with cancer. In particular, research investigating the effects of exercise training among older patients with advanced cancer is lacking. The purpose of the current study is to investigate the effect of a 12-week multimodal and exercise-based intervention among older patients (≥65 years) with advanced pancreatic, biliary tract or lung cancer, who are treated with first-line palliative chemotherapy, immunotherapy or targeted therapy...
September 27, 2018: BMC Cancer
https://www.readbyqxmd.com/read/30241240/outcomes-in-treatment-na%C3%A3-ve-patients-with-metastatic-extremity-osteosarcoma-treated-with-ogs-12-a-novel-non-high-dose-methotrexate-based-dose-dense-combination-chemotherapy-in-a-tertiary-care-cancer-center
#16
Jyoti Bajpai, Arun Chandrasekharan, Vijai Simha, Vikas Talreja, Ashay Karpe, Nikihil Pandey, Ashish Singh, Bharat Rekhi, Tushar Vora, Jaya Ghosh, Shripad Banavali, Sudeep Gupta
PURPOSE: Metastatic osteosarcoma is largely treated with high-dose methotrexate (HDMTX)-based therapy, especially in the pediatric population. This mandates complex pharmacokinetic monitoring in a costly inpatient setting to mitigate unpredictable serious toxicities. Hence, a non-HDMTX-based regimen is worth exploring, especially in India and low- and middle-income countries. MATERIALS AND METHODS: All consecutive treatment-naïve patients with metastatic osteosarcoma were prospectively treated on the novel OGS-12 protocol consisting of sequential doublets of doxorubicin, cisplatin, and ifosfamide...
September 2018: Journal of Global Oncology
https://www.readbyqxmd.com/read/30193538/complete-clinical-remission-of-stage-iv-triple-negative-breast-cancer-lung-metastasis-administering-low-dose-immune-checkpoint-blockade-in-combination-with-hyperthermia-and-interleukin-2
#17
Ralf Kleef, Ralph Moss, A Marcell Szasz, Arthur Bohdjalian, Hans Bojar, Tibor Bakacs
The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days...
December 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/30180874/shenmai-injection-for-the-treatment-of-cancer-related-fatigue-in-advanced-non-small-cell-lung-cancer-patients-undergoing-chemotherapy-study-protocol-for-a-randomized-controlled-trial
#18
Yushu Zhou, Baiming Zhao, Wanyin Wu, Xiaobing Yang, Shunqin Long, Hong Deng, Wenfeng He, Guiya Liao, Qiuping Li, Zhen Xie
BACKGROUND: Cancer-related fatigue (CRF) is the most common symptom in patients with advanced non-small cell lung cancer (NSCLC) undergoing treatment with chemotherapy. However, evidence upon which to base management strategies is scarce. Traditional Chinese Medicine (TCM) has been shown to be beneficial to patients with CRF. Chinese herbal injections should be administered under an evidence-based approach. This trial aims to assess the efficacy and safety of the addition of the Shenmai injection (SMI) to conventional therapy for CRF in NSCLC patients undergoing chemotherapy...
September 4, 2018: Trials
https://www.readbyqxmd.com/read/30173589/oral-vinorelbine-based-concomitant-chemoradiotherapy-in-unresectable-stage-iii-non-small-cell-lung-cancer-a-systematic-review
#19
Paul Lesueur, Isabelle Martel-Laffay, Alexandre Escande, Manon Kissel, Chrystel Locher, Radj Gervais, Roland Schott, Alain Vergnenegre, Christos Chouaid
Cisplatin-based chemotherapy administered concomitantly to thoracic radiotherapy is the treatment recommended by the European guidelines for fit patients with unresectable stage III non-small cell lung cancer (NSCLC). Cisplatin may be combined with etoposide, vinorelbine or other vinca alkaloids, which act also as radiation sensitizers. Initially administered intravenously, vinorelbine is also available as oral formulation and is the only orally available microtubule-targeting agent. In addition, the oral formulation avoids the risk of extravasation and phlebitis...
November 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/30165127/patterns-of-local-regional-failure-after-intensity-modulated-radiation-therapy-or-passive-scattering-proton-therapy-with-concurrent-chemotherapy-for-non-small-cell-lung-cancer
#20
Pei Yang, Ting Xu, Daniel R Gomez, Weiye Deng, Xiong Wei, Hesham Elhalawani, Hekun Jin, Fada Guan, Dragan Mirkovic, Yujin Xu, Radhe Mohan, Zhongxing Liao
PURPOSE: We compared differences in patterns of local-regional failure, and the influence of adaptive planning on those patterns, in patients given passive scattering proton therapy (PSPT) vs. intensity-modulated photon therapy (IMRT) for non-small cell lung cancer. METHODS: Treatment simulation CT scans and dose distributions were registered with images depicting the recurrence. Local failure (LF) was failure within the internal target volume (ITV); marginal failure (MF), as failure between the ITV and PTV plus a 10-mm margin (PTV+10mm ); and regional failure (RF) as those outside the PTV+10mm ...
August 27, 2018: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
109129
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"